Cochrane · systematic review · CD011358
Magnesium for treating sickle cell disease
Than, NN, Soe, HHK, Palaniappan, SK, et al. · Cochrane Database of Systematic Reviews · 2019 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 0 · 0%Low 7 · 50%Moderate 4 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Show all 2 versionsIntravenous magnesium sulphate versus placebo for treating sickle cell disease
Population: people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in frequency of vaso‐occlusive painful crises (as measured by pain diary of days with significant pain) Intravenous magnesium sulphate vs placebo | no estimate extracted | 1 study · 104 participants | Moderate Downgraded: risk of bias, imprecision |
HRQoL score (Child‐reported PedsQL generic scale) at 1 week Intravenous magnesium sulphate vs placebo | no estimate extracted | 1 study · 202 participants | Low Downgraded: risk of bias, imprecision |
HRQoL score (Child‐reported PedsQL multidimensional fatigue scale) at 1 week Intravenous magnesium sulphate vs placebo | no estimate extracted | 1 study · 202 participants | Low Downgraded: risk of bias, imprecision |
HRQoL score (Child‐reported PedsQL sickle cell disease module) at 1 week Intravenous magnesium sulphate vs placebo | no estimate extracted | 1 study · 202 participants | Low Downgraded: risk of bias, imprecision |
Length of hospital stay (hours) Intravenous magnesium sulphate vs placebo | no estimate extracted | 1 study · 104 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: hypotension Intravenous magnesium sulphate vs placebo | RR 2.57 [0.5, 13.08] | 2 studies · 306 participants | Low Downgraded: risk of bias, imprecision |
Adverse effects: warmth at infusion site Intravenous magnesium sulphate vs placebo | RR 13.26 [3.23, 54.4] | 1 study · 202 participants | Low Downgraded: risk of bias, imprecision |
Oral magnesium pidolate versus placebo/no intervention for treating sickle cell disease
Population: people with sickle cell disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Change in frequency of vaso‐occlusive painful crises (as measured by pain diary days with significant pain) Oral magnesium pidolate vs placebo/no intervention | no estimate extracted | 1 study · 24 participants | Low Downgraded: imprecision |
Quality of life Oral magnesium pidolate vs placebo/no intervention | no estimate extracted | NR | No studies |
Length of hospital stay Oral magnesium pidolate vs placebo/no intervention | no estimate extracted | NR | No studies |
Change in dense red cells in sickle cell disease Oral magnesium pidolate vs placebo/no intervention | no estimate extracted | NR | No studies |
Effects of K‐Cl cotransport red cell K+ and Mg2+ content (RBC magnesium) mM/kg Hb Oral magnesium pidolate vs placebo/no intervention | no estimate extracted | 1 study · 24 participants | Moderate |
Adverse events: diarrhoea and headache Oral magnesium pidolate vs placebo/no intervention | no estimate extracted | 1 study · 12 participants | Moderate Downgraded: risk of bias |
Adverse events: including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash Oral magnesium pidolate vs placebo/no intervention | no estimate extracted | 1 study · 36 participants | Moderate Downgraded: risk of bias |